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ABSTRACT
Psoriasis and atopic dermatitis are common,
chronic inflammatory skin diseases. We discuss
several aspects of these disorders, including:
risk factors; incidence and prevalence; the
complex disease burden; and the comorbidities
that increase the clinical significance of each
disorder. We also focus on treatment
management strategies and outline why
individualized, patient-centered treatment
regimens should be part of the care plans for
patients with either psoriasis or atopic dermatitis.
Finally, we conclude that, while our theoretical
knowledge of the optimum care plans for these
patients is increasingly sophisticated, this
understanding is, unfortunately, not always
reflected in daily clinical practice.
Keywords: Atopic dermatitis; Comorbidities;
Disease burden; Epidemiology; Individualized
treatment; Patient-centered treatment; Psoriasis
PSORIASIS: AFFECTS MORE
THAN JUST SKIN AND JOINTS
Introduction
Psoriasis is aheterogeneouschronic inflammatory
disease mediated by the immune system, which
canaffect the skin, nails, and joints [1, 2]. Psoriasis
usually presents as red, scaling plaques on the
scalp, lower back, and extensor aspects of the
elbows and knees. Pustular psoriasis refers to two
types: palmoplantar pustulosis, which forms
painful pustules on the palms and/or soles; and
generalized pustulosis, which is a serious disorder
that appears as sterile pustules anywhere on the
body [3].
Risk Factors
There is evidence that psoriasis may be
hereditary, arising via complex interplay
between multiple genes [4, 5]. Linkage
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analyses suggest that susceptibility to psoriasis
is associated with genes that control
inflammatory immune mechanisms, the cell
cycle, and skin barrier function [5–7].
The histologic features of psoriasis—
epidermal hyperplasia and altered keratinocyte
differentiation—result from innate and adaptive
immune response dysregulation [8]. Cells and
molecules implicated in these immune
responses, particularly activated T cells and
dendritic cells, mediate the development of
psoriasis [8, 9]. The inflammatory pathways
implicated include the interleukin (IL)-23/IL-17
and nuclear factor-jB pathways [8, 10], while
T-helper (Th) 1 and Th22 cells are also
involved [8].
Environmental factors can trigger or
exacerbate outbreaks of psoriasis in genetically
predisposed individuals, including: weight
gain, smoking, alcohol consumption, stress,
withdrawal of corticosteroids, HIV infection,
and the use of medications such as lithium,
beta-blockers, or antimalarial agents [1, 7].
Various microorganisms have also been
implicated in the pathogenesis of psoriasis,
including fungi and viruses [11], although the
strongest link has been provided for streptococcal
infections [12]. Furthermore, obesity andpsoriasis
have overlapping genetic predispositions and
interacting immune functions [13].
Incidence and Prevalence
According to a systematic review of
population-based studies, the incidence of
psoriasis varies according to age and
geographic region, with a greater frequency in
countries more distant from the equator [1].
The prevalence of psoriasis varies from 0%
(Taiwan) to 2.1% (Italy) in children, and from
0.9% (United States) to 8.5% (Norway) in
adults. While psoriasis appears to occur more
frequently in women than men aged B18 years,
the overall incidence between sexes is equal in
adults. In a US study spanning 30 years, the
incidence of psoriasis increased in adults over
time, from 50.8/100,000 person-years between
1970 and 1974 to 100.5/100,000 person-years
between 1995 and 1999 [1].
The Global Psoriasis Atlas, an international,
population-based cohort study, will examine
trends in incidence, prevalence, and mortality
among patients with psoriasis over a 15-year
period [14]. This study will help to address the
need for more global, longitudinal studies
providing such data.
Clinical Significance of Psoriasis
Physical Comorbidities
Psoriasis has been linked with a range of physical
comorbidities [15] including: psoriatic arthritis;
cardiovascular disease; Crohn’s disease; chronic
obstructive pulmonary disease; sleep disorders;
kidney disease; metabolic syndrome; and
non-alcoholic fatty liver disease [16–22].
Psychosocial and Psychiatric Comorbidities
Risk factors for a variety of psychosocial and
psychiatric comorbidities appear to be higher
among patients with psoriasis compared with
the general population [22]. For example,
individuals may become secluded—prompting
depression—when psoriatic lesions appear, thus
treatment may promote an improvement in
mood partly because of an improvement in
psychodynamic issues [23]. Additionally, stress
can exacerbate psoriasis, which itself is a
stress-inducing disease [24].
Medications used to treat comorbidities may
also exacerbate psoriasis in patients, potentially
leading to depression, anxiety, and low
self-esteem [15, 23–25]. Management of
psoriasis should, therefore, incorporate a
strategy to address both physical and
non-physical comorbidities [24].
Burden of Psoriasis
The burden of psoriasis spans physical,
psychologic, and social aspects. At present,
psoriasis is an incurable disease that is often
diagnosed before patients are aged 30 years.
Consequently, individuals may live most of
their adult life with a chronic, debilitating, and
potentially stigmatizing illness [26], which may
not always be acknowledged by clinicians [27].
Moderate-to-severe psoriasis may lead to an
estimated 14 days of work absenteeism per year
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(26 days for severe psoriasis) compared with an
average of 4.4 days in the general population [28].
One study, which assessed work absenteeism and
reduced productivity, estimated that the
psoriasis-associated loss to the UK economy was
approximately £1.07 billion per year, although
the actual loss is likely to be higher due to
comorbid mental health issues and early
retirement through ill health. Prompt referral of
patients with psoriasis to specialist care, and
multidisciplinary management of psoriasis
alongside any comorbid disorders is, therefore,
recommended [28].
Management of Psoriasis
Psoriasis-management decisions should be
based on an assessment of the severity of
disease, the presence of comorbidities, the
need for referral to specialist care, and—where
possible—identification of psoriasis trigger
factors (Fig. 1) [29–31]. A US national survey of
1657 patients with moderate-to-severe psoriasis
found that almost 40% were not receiving
treatment at the time, while around 25% of
those with severe psoriasis received systemic
therapy, phototherapy, or both; and 35%
received topical medications alone [32]. The
Multinational Assessment of Psoriasis and
Psoriatic Arthritis (MAPP) survey was initiated
to gain a greater understanding of the
real-world impact of psoriasis, psoriatic
arthritis, and treatment on patients’ daily lives
[33]. This survey corroborated the results of the
earlier study: moderate-to-severe psoriasis is
under-treated with unmet needs throughout
screening, assessment, and diagnosis
(particularly in the case of psoriatic arthritis)
Fig. 1 Flow diagram highlighting the key decision-making
points and options available for clinicians when assessing
patients with psoriasis [30]. For patients with
mild-to-moderate psoriasis, topical treatment is regarded
as being sufﬁcient, with the addition of ultraviolet (UV)
light in the case of an inadequate response.
Moderate-to-severe disease requires management with
systemic therapy, such as cyclosporin [29, 30]. However,
cyclosporin has been associated with kidney damage, as
well as an increased risk of non-melanoma skin cancer
during UV light treatment, and, therefore, long-term
therapy is not recommended [30, 31]. Similarly,
methotrexate has been linked to hepatotoxicity in patients
with psoriasis and diabetes and/or obesity [30]. Biologic
agents, such as tumor necrosis factor-a antagonists, may be
necessary for patients with psoriatic arthritis who require
rapid and effective disease control [30]. Biologic agents are
associated with higher treatment costs than other
medications, while their use is linked to the development
of harmful anti-drug antibodies and their efﬁcacy may be
reduced in obese patients [30]. (Ref. [30], copyright 2014,
reproduced with permission of Blackwell)
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[34]. Over recent years, a new generation of
biologic treatments for psoriasis has emerged,
including monoclonal antibodies targeting
tumor necrosis factor-a (infliximab,
adalimumab, and etanercept), IL-12/IL-23
(ustekinumab), and IL-17 (secukinumab and
ixekizumab) [35, 36].
General Outcome Measures
Changes in general well-being may be an
important indicator of a patient’s response to
psoriasis treatment. One of the most commonly
used outcome measures for assessing the impact
of psoriasis on quality of life is the Dermatology
LifeQuality Index (DLQI [37,38]).Anotherwidely
used quality-of-life measure is the European
Quality of Life-5 Dimensions (EQ-5DTM)
questionnaire [39], which has been validated in
psoriasis [40]. The Short Form (36) Health Survey
(SF-36) is another non-disease-specificmeasure of
health status, which has shown validity in
psoriasis [40, 41]. These surveys provide useful
assessments of general physical functioning,
including mobility and pain; and psychosocial
functioning, including depression.
Disease-Specific Outcome Measures
The most widely used psoriasis-specific survey
is the Psoriasis Area and Severity Index (PASI),
which quantifies the extent of the disease and
provides an accurate assessment of treatment
efficacy [42]. The PASI provides a composite
index of the three main signs of psoriatic
plaques (erythema, scaling, and thickness)
weighted according to the affected regions of
the body. Another measure of disease severity
is the body surface area (BSA), which
categorizes psoriasis as mild, moderate, or
severe according to the proportion of the
body that is affected [43].
Recurrence of lesions after treatment
discontinuation is a common occurrence in
psoriasis. There is evidence to support the
concept that the expression of some
psoriasis-associated genes in healed lesional
skin remains abnormal after treatment [44].
Gaining an understanding of the processes
involved and continuing to treat these
‘‘invisible’’ lesions may pave the way to
achieve true resolution of disease.
ATOPIC DERMATITIS
Introduction
Atopic dermatitis often begins in childhood,
preceding the development of food allergy
or asthma, and is characterized by intense
itching and recurrent eczematous lesions
[45, 46]. While a defective epidermal barrier
is common to all patients with atopic
dermatitis, it presents as a highly variable
disease [46–48].
Risk Factors
The pathogenesis of atopic dermatitis is not
fully understood: skin barrier defects driven by a
combination of genetic and environmental
factors, and immune dysregulation have been
implicated [45, 49]. The variability in clinical
presentation may be a consequence of the
differing activation of polar immune axes.
Cytokine production differs between patients
with intrinsic (non-allergic) and extrinsic
(allergic) atopic dermatitis [45].
The triggers of atopic dermatitis include
diet, allergen exposure, stress, and irritants.
Environmental factors that could trigger atopic
dermatitis include colonization or infection of
the skin with microbes, such as Staphylococcus
aureus or the Herpes simplex virus. Such
infections would usually trigger keratinocytes
to produce antimicrobial peptides and initiate
an immune response; however, keratinocytes
from the skin of patients with atopic
dermatitis are deficient in their ability
to produce antimicrobial peptides [45]. In
addition, the gut microbiome may be a
factor, with gut bacterial depletion and
altered metabolic activity at the age of
3 months being implicated in childhood
atopy and asthma [50].
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Incidence and Prevalence
Atopic dermatitis is the most common chronic
inflammatory skin disease. The prevalence of
the disease in Western countries has increased
over the past 30 years, and approximately
15–20% of children and 1–3% of adults may
be affected [48, 51]. Although it is commonly
perceived as being primarily a childhood
disease, atopic dermatitis may persist through
to adulthood in up to 50% of cases.
Furthermore, ‘‘late-onset’’ (at age 40 years?)
and ‘‘very late-onset’’ (at age 60 years?) atopic
dermatitis is increasingly being diagnosed [45].
Clinical Significance of Atopic Dermatitis
Physical Comorbidities
Atopic dermatitis is often accompanied by
allergic rhinitis, asthma, and food allergy (the
‘‘atopic march’’), as well as conjunctivitis
[49, 52]. The prevalence of asthma among
children with atopic dermatitis ranges from
14.2 to 52.7%, while 75% of children with
severe atopic dermatitis develop allergic rhinitis
[52]. The incidence of food allergies among
those with atopic dermatitis appears to be more
common than in the general population, but
obtaining exact figures is hampered by varying
definitions adopted across studies [52].
Psychiatric Comorbidities and Burden
of Disease
An association has been found between an
increased severity of atopic dermatitis and a
greater frequency of psychologic disturbances,
including anxiety, depression, attention deficit
hyperactivity disorder, autism, and suicidal
ideation [52]. This supports the need to
effectively manage the disease in order to
improve the general well-being and quality of
life of patients and their families [53, 54]. For
example, parents of children with atopic
dermatitis may be affected because of the
time-consuming nature of implementing
treatment regimens or dietary and household
changes. Also, atopic dermatitis can have a
substantial financial impact on both individual
families and society (with US societal estimates
ranging from\$100 to[$2000 per patient per
year) [55].
Optimal management of atopic dermatitis
requires a full appreciation of the breadth of the
burden that it imparts. Targeting parents and
caregivers with educational and psychosocial
support can help to alleviate this burden, with
improved medical, psychosocial, and family
outcomes having the potential to decrease the
associated financial costs [55]. Scoring Atopic
Dermatitis (SCORAD) is a composite index that
was developed as a means of quantifying the
extent, severity, and subjective symptoms of
atopic dermatitis as an indicator of its clinical
burden [56].
Management of Atopic Dermatitis
For the past several years, the topical
application of corticosteroids and calcineurin
inhibitors (e.g., tacrolimus and pimecrolimus)
has represented the mainstay of
anti-inflammatory therapy for atopic dermatitis
[57]. However, since atopic dermatitis is such a
varied disorder, there is an argument to stratify
patients into distinguishable endotypes and
phenotypes to better inform treatment
decisions. Successful management of atopic
dermatitis incorporates skin hydration, skin
barrier repair, topical anti-inflammatory
medications (e.g., corticosteroids), control of
infection, and elimination of exacerbating
factors. As there are no cures for food allergy or
asthma, effective treatments for atopic dermatitis
may be important for preventing the natural
course of the ‘‘atopic march’’ [45].
Different treatment approaches may be
appropriate for patients with extrinsic and
intrinsic disease, as only extrinsic atopic
dermatitis is associated with high levels of serum
immunoglobulin E. The pathogenesis of both is
largely driven by T cells, and treatment with
cyclosporin, which suppresses T-cell activation,
can be successful [58]. However, the differential
expression of other immune molecules, such as
IL-17, IL-22, and IL-23/IL-12p40, may be
significant for the differential treatment of
extrinsic and intrinsic atopic dermatitis [58].
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Two recent studies have shown that
neonates at high risk for atopic dermatitis can
be prevented from developing the disease
through the application of emollients from
birth, which improves skin hydration and
reduces skin permeability to allergens, thereby
potentially correcting the subclinical
dysfunction of the skin barrier and controlling
the inflammatory process [59, 60]. Further
studies may show whether this approach could
reduce the incidence of food allergies as part of
the ‘‘atopic march’’ [59, 60].
The skin microbiome is believed to be
correlated with atopic dermatitis [61].
Staphylococcus aureus infections may predispose
a patient to disseminated viral skin infections,
which may be critical to outcomes in small
children with atopic dermatitis [62].
There are conflicting reports on the
importance of diet in the management of
atopic dermatitis [63]. Low-level evidence
suggests that the use of probiotics by pregnant
and nursing mothers, or infants, reduces the risk
of atopic dermatitis in infants [64]. In children
likely to have vitamin D deficiency during the
winter months, vitamin D supplementation has
been shown to produce a clinically and
statistically significant improvement in
winter-related atopic dermatitis [65].
Future Treatment Options
Patients with atopic dermatitis often require
systemic, immunomodulating, and
immunosuppressive therapy, but the use of
such regimens can be hampered by toxicity
and inadequate response [66]. Interferon-c
induces heightened immune surveillance and
immune system function during infection [67].
Treatment with recombinant interferon-c is
well-tolerated in patients with severe,
unremitting atopic dermatitis, with clinical
improvement reflecting decreases in absolute
white blood cell and eosinophil counts [68].
This type of therapy shows particular promise
among pediatric patients with atopic dermatitis,
although further studies are needed to
determine the effects of interferon-c on the
prevalence of skin infection [69].
Several cytokines have been implicated in
atopic allergic disease [70, 71]. Treatment with
the fully human immunoglobulin-G1
monoclonal antibody ustekinumab, which
binds to IL-12 and IL-23 and prevents
upregulation of IL-17-producing T cells, was
associated with marked clinical improvement in
a patient with refractory atopic dermatitis [66].
This follows the successful use of ustekinumab
in patients with psoriasis, which also involves
IL-12 and IL-23 [72]. In addition, evidence has
indicated that dupilumab, a monoclonal
antibody targeting IL-4 receptor a, may lead to
a rapid improvement in atopic dermatitis across
almost all measures of disease activity, with
relatively mild and non-dose-limiting side
effects. This is, therefore, a promising therapy
for all moderate-to-severe cases of atopic
dermatitis, regardless of endotype or
phenotype [73–75].
Another target for the potential treatment of
atopic dermatitis is cyclic adenosine
monophosphate phosphodiesterase, which is
present at an abnormally high level in the
leukocytes of patients with the disease [76].
Selective inhibition of phosphodiesterase with
topical cipamfylline was efficacious in the
treatment of atopic dermatitis, although
results were inferior to those achieved with
topical hydrocortisone [76]. Greater potential
has been shown for the newer
phosphodiesterase inhibitors, apremilast and
topical AN2728, although few studies have
been published and the long-term impact of
treatment is unknown [77]. Future treatment
options for atopic dermatitis have been




An individualized, patient-centered approach is
essential for the effective management of
psoriasis and atopic dermatitis, and their
associated comorbidities (Fig. 2). Future
directions for psoriasis and atopic dermatitis
treatments may arise from more precise
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definitions of endotypes, which could facilitate
tailored treatment plans. Such tailoring could
mean that initiating treatment at an earlier age
will help minimize or reduce comorbidities,
thereby improving quality of life and reducing
the detrimental impact on a patient’s home and
work life. In addition, effective and appropriate
education of patients and their family and/or
support network is of prime importance.
Psoriasis and atopic dermatitis are chronic
diseases that require patients to receive
long-term treatment. While these disorders
have a detrimental impact on many aspects of
patients’ lives, patients may sometimes feel that
this is not fully appreciated by their doctors.
Crucially, good interpersonal communication
between doctors and patients is the key to
treatment success.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
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